300016 Stock Overview
Researches, develops, produces, and sells pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Beijing Beilu Pharmaceutical Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥6.06 |
| 52 Week High | CN¥8.97 |
| 52 Week Low | CN¥3.58 |
| Beta | 0.42 |
| 1 Month Change | -14.89% |
| 3 Month Change | 5.03% |
| 1 Year Change | -11.79% |
| 3 Year Change | -34.77% |
| 5 Year Change | -32.89% |
| Change since IPO | -57.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300016 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -0.8% | -2.4% | -1.5% |
| 1Y | -11.8% | -7.4% | 5.6% |
Return vs Industry: 300016 underperformed the CN Pharmaceuticals industry which returned -6% over the past year.
Return vs Market: 300016 underperformed the CN Market which returned 6.9% over the past year.
Price Volatility
| 300016 volatility | |
|---|---|
| 300016 Average Weekly Movement | 7.3% |
| Pharmaceuticals Industry Average Movement | 5.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in CN Market | 11.2% |
| 10% least volatile stocks in CN Market | 4.4% |
Stable Share Price: 300016 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300016's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 952 | Xu Wang | www.beilu.com.cn |
Beijing Beilu Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. The company's products include contrast agents, central nervous system products, and oral anti-diabetic drugs. Beijing Beilu Pharmaceutical Co., Ltd.
Beijing Beilu Pharmaceutical Co., Ltd Fundamentals Summary
| 300016 fundamental statistics | |
|---|---|
| Market cap | CN¥2.98b |
| Earnings (TTM) | -CN¥49.30m |
| Revenue (TTM) | CN¥970.62m |
3.1x
P/S Ratio-60.5x
P/E RatioIs 300016 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300016 income statement (TTM) | |
|---|---|
| Revenue | CN¥970.62m |
| Cost of Revenue | CN¥549.91m |
| Gross Profit | CN¥420.71m |
| Other Expenses | CN¥470.01m |
| Earnings | -CN¥49.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 18, 2025
| Earnings per share (EPS) | -0.10 |
| Gross Margin | 43.34% |
| Net Profit Margin | -5.08% |
| Debt/Equity Ratio | 46.6% |
How did 300016 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/09 12:23 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Beijing Beilu Pharmaceutical Co., Ltd is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yalei Yan | Bohai Securities Co., Ltd. |
| Shuchang Liu | Changjiang Securities Co. LTD. |
| Jie Ma | Cinda Securities Co., Ltd |